HOME >> BIOLOGY >> NEWS
NIH establishes Rare Diseases Clinical Research Network

To address the challenges inherent in diagnosing and treating rare diseases, the National Institutes of Health (NIH) announced today the establishment of the Rare Diseases Clinical Research Network. With $51 million in grant funding over five years from several NIH components,* the network will consist of seven Rare Diseases Clinical Research Centers (RDCRCs) and a Data and Technology Coordinating Center (DTCC).

"Funding research on rare diseases is a vital aspect of the NIH mission," said NIH Director, Elias A. Zerhouni, M.D. "By encouraging cooperative partnerships among the investigators at these centers, we hope to accelerate the development of diagnostics and treatments that will benefit these important patients."

The RDCRCs and the DTCC will be located at the following institutions:

  • Baylor College of Medicine, Houston, TX -- Rare Disease Clinical Research Center for New Therapies and New Diagnostics -- Dr. Arthur L. Beaudet

  • Boston University School of Medicine, Boston, MA -- Vasculitis Clinical Research Network -- Dr. Peter A. Merkel

  • Children's Hospital Medical Center, Cincinnati, OH -- Rare Lung Diseases Clinical Research Network -- Dr. Bruce C. Trapnell

  • Children's National Medical Center, Washington, DC -- Rare Diseases Clinical Research Center for Urea Cycle Disorders -- Dr. Mark L. Batshaw

  • The Cleveland Clinic Foundation, Cleveland, OH -- Bone Marrow Failure Clinical Research Center -- Dr. Jaroslaw P. Maciejewski

  • University of Rochester, Rochester, NY -- Nervous System Channelopathies Pathogenesis and Treatment -- Dr. Robert C. Griggs

  • Weill Medical College of Cornell University, New York, NY -- The Natural History of Rare Genetic Steroid Disorders -- Dr. Maria I. New

  • H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL -- The Data and Technology Coordinating Center -- Dr. Jeffrey P. Krisch
    '"/>


Contact: Joyce McDonald
info@ncrr.nih.gov
301-435-0888
NIH/National Center for Research Resources
3-Nov-2003


Page: 1 2 3 4

Related biology news :

1. Tufts University establishes $4 million dollar tissue engineering resource center
2. DFG establishes first German-Sino Research Training Group
3. DFG establishes 14 new research units
4. $8 million grant establishes program to uncover genetics of asthma
5. Hemocellular Therapeutics establishes licensing agreement with UNC, ECU
6. New research establishes genetic associations in hepatitis C
7. NSF establishes center for biophotonics at UC Davis
8. NIH funding establishes a chimpanzee sanctuary
9. Guyana establishes its first conservation concession
10. USDA establishes Honeybee Genetics and IPM Center
11. Scientist finds genetic clues to Alzheimers, establishes DNA bank for future studies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH establishes Rare Diseases Clinical Research Network

(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
(Date:5/24/2013)... WI (PRWEB) May 24, 2013 ... the discovery and development of calcium-binding proteins to ... of safety assessment study of apoaequorin ... international journal published for the British Industrial Biological ... study was to investigate potential adverse effects, if ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... May 23, 2013 Graphite Metallizing ... self-lubricating bushings mounted in stainless steel pillow blocks. ... of GRAPHALLOY with the application and installation versatility ... Pillow Blocks work exceptionally well when submerged ... hostile liquids such as acids, alkalies, hydrocarbons, black ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
Cached News: